NASDAQ:CARA - Cara Therapeutics Stock Price, Forecast & News

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics Inc (NASDAQ:CARA) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.15. The biopharmaceutical company earned $5.79 million during the quarter, compared to analysts' expectations of $5.56 million. Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. View Cara Therapeutics' Earnings History.

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Cara Therapeutics.

4 equities research analysts have issued 12 month target prices for Cara Therapeutics' shares. Their forecasts range from $30.00 to $39.00. On average, they expect Cara Therapeutics' stock price to reach $33.80 in the next twelve months. This suggests a possible upside of 120.2% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

News stories about CARA stock have been trending extremely negative on Thursday, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cara Therapeutics earned a coverage optimism score of -4.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Cara Therapeutics.

Cara Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,850,000 shares, a drop of 9.7% from the January 15th total of 5,370,000 shares. Based on an average trading volume of 729,500 shares, the days-to-cover ratio is presently 6.6 days. Currently, 11.4% of the company's stock are sold short. View Cara Therapeutics' Current Options Chain.

Some companies that are related to Cara Therapeutics include ArQule (ARQL), Uniqure (QURE), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Insmed (INSM), Arena Pharmaceuticals (ARNA), Synthorx (THOR), Ra Pharmaceuticals (RARX), Forty Seven (FTSV), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Cambrex (CBM), Prestige Consumer Healthcare (PBH), Pacira Biosciences (PCRX) and Karuna Therapeutics (KRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), 22nd Century Group (XXII), Insys Therapeutics (INSY), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Novavax (NVAX) and BioMarin Pharmaceutical (BMRN).

Cara Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wealth Quarterback LLC (351.62%), Farallon Capital Management LLC (5.75%), Chescapmanager LLC (3.25%), State Street Corp (2.50%), Franklin Resources Inc. (1.41%) and Geode Capital Management LLC (1.35%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.

CARA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Ladenburg Thalmann Financial Services Inc., Franklin Resources Inc., Exane Derivatives, DekaBank Deutsche Girozentrale and Advisor Group Inc.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.

CARA stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Bank of America Corp DE, Cypress Capital Management LLC WY, Farallon Capital Management LLC, Pinnacle Associates Ltd., J. Goldman & Co LP, AdvisorShares Investments LLC and State Street Corp. View Insider Buying and Selling for Cara Therapeutics.

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CARA stock can currently be purchased for approximately $15.35.

Cara Therapeutics has a market capitalization of $614.43 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.

The official website for Cara Therapeutics is http://www.caratherapeutics.com/.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.